Meeting Coverage
EHA
European Hematology Association
Latest EHA Meeting Coverage
Near-80% reduction in PFS hazard with ibrutinib-venetoclax versus obinutuzumab-chlorambucil
Better response rates and survival with axicabtagene ciloleucel versus external control group
Better overall response rate, less cardiotoxicity, with second-generation BTK inhibitor
Frontline venetoclax plus azacitidine adds 5 months to median OS versus azacitidine alone
Anti-CD38 therapy added to conventional regimen boosts PFS in trial
Checkpoint inhibitor improved PFS in refractory and transplant-ineligible cases
Triplet regimen significantly extended median PFS versus doublet in IKEMA study
More quizartinib-treated patients went on to stem cell transplant
Preexisting aberrant B-cell clone implicated
Three drugs produce high response rates for CLL. Is one of them safer?
Progression-free survival doubled with carfilzomib versus bortezomib
Durable responses with daratumumab seen after multiple prior regimens
Adding elotuzumab boosts median progression-free survival by almost 5 months.
Latest Oncology/Hematology Meeting Coverage
-
AHNS: American Head & Neck Society
July 2023
-
ASCO Future Focus: Immunotherapy: Future Focus from the American Society of Clinical Oncology
June 2023
-
ASCO Video Pearls: Immunotherapy: Video Pearls from the American Society of Clinical Oncology
June 2023
-
ASCO Video Pearls: Renal Cell Carcinoma: Video Pearls from the American Society of Clinical Oncology
June 2023